Kornimate/medical-research-clean huggingface dataset:
a prospective cohort study on colorectal cancer screening in community population

Conditions: Colorectal Cancer

Summary: this study will validate the real world results of polygene methylation detection in colorectal cancer in a large prospective community cohort. in this study, questionnaire survey and polygene methylation detection technology of colorectal cancer were used as preliminary screening methods, and colonoscopy was used as further validation examination method to screen colorectal cancer and precancerous lesions. the diagnosis and outcome of all lesions were based on colonoscopy and pathological examination.

1. the informed consent signed by shougang community will be completed in the baseline period: colorectal cancer risk factors assessment questionnaire, medical history collection, fecal immunochemical (fit), carcinoembryonic antigen (cea) blood test and blood bowel cancer gene methylation detection, for colorectal cancer gene methylation detection results more positive subjects and the result of the negative part of the subjects (n = 500), within 3 months after receiving the results complete colonoscopy. 2. follow-up at 1, 2, 3, 4, and 5 years after baseline included: ① central follow-up at 1, 3, and 5 years: history collection, colonoscopy, fit test, and cea examination; ② telephone follow-up at the 2nd and 4th years: medical history was collected; (3) survival outcome registration was performed in the fifth year; follow-up history was collected at 1, 2, 3, 4, and 5 years after completion of baseline, and survival outcomes were registered at 5 years. 3. during the follow-up, the subjects were confirmed to be diagnosed with colorectal cancer by evaluation (colorectal cancer was diagnosed by colonoscopy), and the subjects who were treated after polyps or adenomas were found during colonoscopy also reached the study endpoint.

Eligibility criteria:
inclusion criteria: 1. chronological age ≥40 years; 2. full capacity for action; 3. after enrollment, the participants were able to complete the colorectal cancer risk factor assessment questionnaire and the annual follow-up interviews; 4. in the course of the study, the information related to tumor diagnosis in other hospitals can be timely fed back to the researchers; exclusion criteria: 1. history of colorectal cancer and other malignant tumors; 2. previous colorectal resection; 3. undergoing any cancer-related treatment; 4. patients who have received major surgical treatment such as blood transfusion or transplantation within 3 months; 5. participate in other interventional clinical investigators within 3 months; 6. pregnant or lactating women; 7. have autoimmune disease, hereditary disease, mental illness/disability, etc 8. poor compliance, unable to complete the study.

Keywords: ctdna methylation community population screening
comparison between robotic, endoscopic and traditional open surgery in thyroidectomy

Conditions: Endoscopy; Robotics; Thyroidectomy; Papillary Thyroid Carcinoma

Summary: comparison of endoscopic thyroidectomy, robotic thyroidectomy and conventional open surgery, the safety of the operation, the timing of the operation and the complications.

with the further development of endoscopic technique, thyroid surgery of the robot has emerged, which may become a trend of endoscopic technology due to its convenience and accuracy.in this study, the advantages and disadvantages of endoscopic thyroidectomy and robotic thyroid surgery were compared, and the experience in the transition stage of thyroid surgery in robotic and endoscopic thyroidectomy was summarized.

Eligibility criteria:
inclusion criteria: * thyroid papillary carcinoma. * the tumor diameter is less than or equal to 1cm. * the lymph nodes are limited to the vi level. * voluntary choice of endoscopy or robotic surgery. exclusion criteria: * patients without beauty needs. * there is lateral neck or mediastinal lymph node metastasis. * the tumor invades the nerve and surrounding organs.

Keywords: endoscopy robotics thyroidectomy papillary thyroid carcinoma
effects of wb-ems and protein supplementation on lbm maintenance during intended weight loss

Conditions: Overweight; Obesity; Abdominal Obesity

Summary: the present study aimed to determine the effect of different interventions on lean body mass maintenance under weight loss conditions in overweight and obese premenopausal women. three study groups were implemented: (1) protein supplementation (only) group (2) protein supplementation and walking intervention (3) protein supplementation, walking and wb-ems-application. all protocols were applied for 16 week of intervention. a energy deficit of 500 kcal/d was intended however while group (1) focus consistently on energy restriction (500 kcal/d), in group (2) and (3) a combined physical activity (i.e. walking with a volume representing 250 kcal/d) and energy restriction (250 kcal/d) protocol was applied. total protein uptake including protein supplementation was calculated to average around 1.2 g/kg body mass per day in groups (1) and 1.5 g/kg body mass/d in group (2) and (3). wb-ems was applied 1.5x 20 min/week (i.e. each tuesday and every second thursday). primary study endpoint was lbm as determined by dual energy x-ray absorptiometry.


Eligibility criteria:
inclusion criteria: * premenopausal women 25-50 years old * overweight/obesity (body fat rate equal or higher 30%) exclusion criteria: * medication and diseases affecting muscle and fat metabolism * pregnant or parturition \< 6 months * any condition or medication that prevent proper physical activity or wb-ems application * holidays equal or more than 1 week during the intervention period * other interventions with impact on the primary and core secondary outcome (i.e. body fat parameters) started during the last year.

Keywords: exercise electromyostimulation protein weight reduction
comparison of biphasic insulin aspart 70/30 versus insulin glargine in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in the united states of america (usa). the purpose of this study is to test whether biphasic insulin aspart 70/30 twice a day with metformin improves glycemic control vs. once daily insulin glargine with metformin in subjects with type 2 diabetes who are inadequately controlled on basal insulin plus oral anti-diabetic therapy.


Eligibility criteria:
inclusion criteria: * type 2 diabetes

Keywords: type 2 diabetes
study evaluating the effects of air645 on allergen-induced airway responses in subjects with mild atopic asthma

Conditions: Asthma

Summary: to assess the efficacy of inhaled air645 in the suppression of the asthmatic responses in subjects with mild asthma inhaling an allergen.


Eligibility criteria:
inclusion criteria: * men and women with well controlled mild allergic asthma, aged 18 to 65 years * only asthma med is short-acting bronchodilator used not more than twice weekly * fev1 greater than 70% predicted and a demonstrated baseline late response to allergen induction

Keywords: hypersensitivity lung diseases, obstructive immune system diseases respiratory tract diseases bronchial diseases lung diseases hypersensitivity, immediate asthma respiratory hypersensitivity
comparison of adalimumab and infliximab treatment of rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to establish whether ra patients with moderate to severe disease activity with unsustainable response to infliximab 3 mg/kg every 8 weeks have better efficacy with adalimumab 40 mg s.c. eow compared to infliximab 3 mg/kg i.v. every 6 weeks.


Eligibility criteria:
inclusion criteria: * acr criteria fulfilled,das28-3(crp \> 3.2 * \> 6 months prior treatment with infliximab 3 mg/kg i.v. every 8 week with initial response * fading clinical response to infliximab * negative pregnancy test (women with childbearing potential) * use of reliable method of contraception (women with childbearing potential) * informed consent exclusion criteria: * age less than 18 years * lack of co-operability * positive serology for hepatitis b or c * history of positive hiv status * history of tb or untreated latent tb * histoplasmosis or listeriosis * pregnancy or breastfeeding * persistent or recurrent infections * history of cancer * uncontrolled diabetes * ischaemic heart disease * congestive heart failure (nyha 3-4) * active inflammatory bowel disease * recent stroke (within 3 months) * history of or current inflammatory joint disease other than ra * previous diagnosis or signs of central nervous system demyelinating disease
main-image registry

Conditions: Coronary Artery Disease

Summary: all comers registry with patients with chronic coronary syndrome or acute coronary syndrome who underwent intracoronary imaging during cardiac catherization. the aim is to identify plaque characteristics on oct or ivus that are associated with adverse cardiac events including myocardial infarction and atherosclerotic progression.


Eligibility criteria:
inclusion criteria: patients undergoing pre-intervention optical coherence tomography imaging exclusion criteria: -
interval versus continuous training in lvad patients

Conditions: Heart Failure

Summary: patients with a left ventricular assist device (lvad) will be randomized to either a moderate continuous (mct, 50-60% of vo2peak) or interval training (it, 80-90% of vo2peak) group for 6 weeks with 3 sessions per week, lasting for 20 minutes. an additional 10 minutes of resistance training will be performed in each group. improvement of vo2peak and quality of life (kccq score) between the groups will be assessed.

in- and out-patients with left ventricular assist device (lvad) will be recruited to participate. on consent to participate, patients will be randomized to either moderate continuous (mct) or interval (it) training. an initial cardiopulmonary exercise test (cpet) will be performed to assess exercise intensity levels using a ramp protocol. baseline quality of life (kccq score), echocardiographic and lvad parameters, lab works, including ntprobnp, a 6min walk distance (6 mwd) will be assessed. patients will then receive 6 weeks of supervised training in our facility (3x/week, 30min each). following these sessions cpet, lab works, kccq assessment, 6 mwd, and echocardiography will be performed to assess improvement of exercise capacity. patients in the mct group will receive 20min of moderate, continuous bicycle training at an intensity of 50-60% of vo2peak, the it group will increase exercise density by increasing the duration of intense bouts (80-90% of vo2peak) over the weeks. all groups will receive an additional 10 minutes of resistance training (total exercise time 30 minutes in both groups). improvement of vo2peak and quality of life (kccq score) between the groups will be assessed.

Eligibility criteria:
inclusion criteria: * age\>18 years * clinically stable lvad patients with terminal heart failure * written informed consent * the mental and physical ability to exercise exclusion criteria: * established contraindications for exercise testing * systemic blood stream infection

Keywords: exercise capacity vo2peak interval training
the effect of intraoperative ketamine on opioid consumption and pain after spine surgery in opioid-dependent patients

Conditions: Postoperative Pain; Chronic Pain; Analgesics

Summary: patients with a daily use of opioids may develop higher postoperative pain levels, often need high doses of morphine and therefore their pain may be difficult to treat. a low dose of an old anesthetic drug, ketamine, administered during surgery can possibly reduce pain and morphine consumption in these patients. our purpose is to investigate the effect of low dose ketamine on morphine consumption and pain after spine surgery in patients with a daily use of opioids. our hypothesis is that low dose ketamine can reduce morphine consumption, pain and side-effects after spine surgery.

opioid-dependent patients can develop hyperalgesia and often have a high opioid consumption postoperatively due to opioid tolerance. intraoperative ketamine in subanesthetic doses can possibly reduce hyperalgesia and reduce opioid-tolerance in these patients. ketamine is a non-competitive n-methyl-d-aspartate (nmda) receptor antagonist that works by blocking the nmda receptors in the central and peripheral nerve system. it can be used for general anesthesia but the drug also has other properties including lowering of central excitability and reducing postoperative opioid tolerance by modeling the opioid receptors. further more it can possibly reduce chronic pain by blocking wind-up effect when blocking the nmda receptors. our purpose is to investigate the effect of intraoperative ketamine on opioid consumption and pain after spine surgery in opioid-dependent patients. our hypothesis is that ketamine can reduce opioid consumption and reduce postoperative pain and side effects compared to placebo.

Eligibility criteria:
inclusion criteria: * patients undergoing lumbar spinal fusion surgery in general anesthesia. * daily use of opioids for a minimum of 6 weeks preoperatively (morphine, ketobemidone, oxycodone, fentanyl, tramadol and/or buprenorphine). * back pain for a minimum of 3 months preoperatively. * age \> 18 years and \< 85 years. * asa 1-3. * bmi \> 18 and \< 40. * fertile women need to have a negative urine hcg pregnancy test. * patients who have given their written informed consent to participate in the study after understanding the content and limitations of the study exclusion criteria: * participation in another concomitant drug trial. * patients who do not understand or speak danish. * allergy to the drugs used in the trial. * abuse of drugs - as assessed by the investigator. * daily methadone use. * increased intraocular pressure - assessed from the patients chart. * uncontrolled hypertension - assessed from the patients chart. * previous and current psychotic episodes - assessed from the patients chart

Keywords: morphine consumption postoperative pain ketamine side effects spine surgery chronic pain
study to evaluate the care process and the quality of stemi care

Conditions: Myocardial Infarction; Acute Coronary Syndrome

Summary: cardiovascular diseases, and more precisely patients with st - elevated myocardial infarction are globally responsible for a large number of hospitalizations and deaths. monitoring the quality of care for these patients is very relevant topic. investigators developed indicators from the scientific literature on the quality of care for patients with stemi at both the patient level and hospital level. the indicators were subsequently validated by a rand modified delphi - study of multidisciplinary experts in the care of patients with stemi. in this study, the following objectives are set: 1. ) study of the quality of care for patients with stemi in 16 flemish hospitals with cardiology department by retrospective and prospective audit of 20 patient records per participating hospital . 2. ) study of the interdisciplinary relationships and communication within teams involved in the care of patients with stemi in the participating hospitals 3) study of perceived organization of care for patients with stemi in the participating hospitals in accordance with the objectives of the research, the study consists of three phases: 1. ) a retrospective observational audit of 20 patient records of patients with stemi each participating hospital. 2. ) a prospective observational audit of 20 patient records of patients with stemi each participating hospital. 3. ) a survey using validated instruments of interdisciplinary relationships and communication on the one hand and on the other by the teams involved in the care of patients with stemi perceived organization of care . data collection is performed by local researchers and remains their property. the data is coded and kept confidential. only the local researcher has access to the encryption key. the data are protected by the belgian law on privacy and medical confidentiality, only to be used in the context of this study. the results are published anonymously.


Eligibility criteria:
inclusion criteria: * patients admitted with stemi within 24 hours after symptom onset and * eligible for reperfusion according to esc stemi guidelines exclusion criteria: -
apatinib and etoposide capsule versus apatinib in patients with platinum resistant ovarian cancer

Conditions: Ovarian Cancer

Summary: the study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) or apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or refractory ovarian cancer compared with apatinib (375 mg qd).


Eligibility criteria:
inclusion criteria: 1. female patients, ≥18 years. 2. epithelial ovarian, fallopian tube or primary peritoneal cancer 3. platinum refractory and resistant disease (disease progression during platinum therapy or within \<6 months of platinum therapy) 4. eocg performance status of 0-2 exclusion criteria: 1. non-epithelial tumours 2. ovarian tumours with low malignant potential 3. surgery (including open biopsy) within 4 weeks before starting study therapy or anticipated need for major surgery during study treatment 4. evidence of rectosigmoid involvement by pelvic examination, bowel involvement on computed tomography, or clinical symptoms of bowel obstruction.
multi-center randomized clinical trial irreversible electroporation for the ablation of localized prostate cancer

Conditions: Prostate Cancer

Summary: multi-centre randomized clinical trial: 106 patients with confirmed unilateral high-volume low risk (gleason score 3 + 3) or intermediate risk prostate cancer (gleason score 3 + 4) will undergo an ire treatment. these patients will be randomized into one of the two groups of the study. group 1: focal ablation of the prostate at the side of the positive biopsies (focal-ablation) group 2: extended ablation of the prostate (extended ablation) patients will have an ultrasound of the prostate and the imaging data will be entered into the planning software system of the ire-device. the volume of the prostate is measured and a specified ablation zone will be determined. the patients will be admitted for overnight stay in the hospital on the morning of the scheduled ire procedure. the ire will be performed under general anaesthetic and the specified zone identified in the planning stage will be ablated. two to four ire electrode needles will be placed into the prostate under ultrasound image guidance with a perineal approach using a brachytherapy grid. when the needles are in place, electric pulses of one to two minutes duration are used to ablate the specified zone. the total procedure time will be approximately 1 hour. safety data will be collected and patients will be followed up at 1 day post-operatively, 1 month, 3 months, 6 months and 1, 2 and 3 year(s) post ire.


Eligibility criteria:
inclusion criteria 1. histologically confirmed organ-confined unilateral prostate cancer with adjacent positive biopsies on transperineal template prostate biopsies or mri targeted biopsies in combination with systematic biopsies (clinical stage t1c-t2b) 2. gleason sum score 6 or 7 3. psa \ 15 ng/ml counselled with caution 4. life expectancy of \> 10 years exclusion criteria 1. bleeding disorder as determined by prothrombin time (pt) \> 14.5 seconds, partial thromboplastin time (ptt) \> 34 seconds, and platelet count \< 140/ul 2. no ability to stop anticoagulant or anti-platelet therapy for 7 days prior the procedure. 3. active urinary tract infection (uti) 4. history of bladder neck contracture 5. anaesthesia surgical assignment category iv or greater 6. history of inflammatory bowel disease 7. concurrent major debilitating illness 8. prior or concurrent malignancy except for basal cell carcinoma of the skin 9. cardiac history including arrhythmias, icd or pacemaker 10. prostate calcifications greater than 5 mm. 11. biologic or chemotherapy for prostate cancer 12. hormonal therapy for prostate cancer within 6 months prior to procedure 13. previous radiation to pelvis 14. transurethral resection of the prostate / urethral stent 15. prior major rectal surgery (except haemorrhoids)

Keywords: focal therapy irreversible electroporation unilateral prostate cancer
role of surgery in treatment of recurrent brian glioma:prognostic factors and outcome

Conditions: Recurrent Glioma; Glioma, Malignant

Summary: role of surgery in treatment of recurrent brain glioma prognostic factors and outcome measures role of surgery : in patients with grade i gliomas, such as pilocytic astrocytomas, resection is potentially curative. for more diffuse invasive gliomas (grade ii or higher), initial management typically includes maximal safe resection when possible. increasing evidence supports an association between extent of resection and prolonged progression-free and overall survival for patients with diffuse gliomas of all types and grades many studies reported that more that 90%of patients with glioma showed recurrence at the orginal tumor location. review the outcomes of re-operation in treatment of recurrent brain gliomas to determine the prognostic factors which can predict which patient would benefit from multiple surgery . trail to improve the outcome of these patients and decrease rate of complications


Eligibility criteria:
inclusion criteria: - patient previously operated and documented as a glioma with clinical and neuroimaging and pathological evidences. patients who will undergo re-operation for treatment of a recurrent brain glioma at the time of study(one year) histological types : different histological types of glioma. exclusion criteria: * patients has brain glioma that is de novo patients who are unfit for any neurosurgical interventions. multicentric recurrent glioma.